Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2023

Segment Reporting [Abstract]

Summary of Financial Information with Respect to Reportable Segments

Presented below is financial information with respect to the Company’s reportable segments for the periods presented:

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Segment revenues:
Software	$	29,352	$	30,011	$	61,565	$	63,092
Drug discovery	5,837		8,458		38,406		24,040
Total segment revenues	$	35,189	$	38,469	$	99,971	$	87,132
Segment gross profit:
Software	$	22,657	$	22,910	$	47,755	$	48,480
Drug discovery	(8,847)		(5,776)		11,748		(3,363)
Total segment gross profit	13,810		17,134		59,503		45,117
Unallocated:
Research and development	(42,705)		(31,123)		(83,446)		(58,945)
Sales and marketing	(9,022)		(7,428)		(18,167)		(14,099)
General and administrative	(23,216)		(22,056)		(49,524)		(44,189)
Gain on equity investments	—		11,828		147,322		11,828
Change in fair value	40,654		(15,700)		76,391		(21,864)
Other income (expense)	4,326		(308)		7,263		31
Income tax benefit (expense)	20,431		(33)		(5,928)		(5)
Consolidated net income (loss)	$	4,278	$	(47,686)	$	133,414	$	(82,126)

Schedule of Revenues by Geographic Area

The following table sets forth revenues by geographic area for the three and six months ended June 30, 2023 and 2022:

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
United States	$	23,964	$	27,104	$	74,308	$	57,379
APAC	6,237		2,966		13,310		4,523
EMEA	4,832		5,106		11,660		17,751
Rest of World	156		3,293		693		7,479
	$	35,189	$	38,469	$	99,971	$	87,132